A Phase 2 interventional study of bevacizumab and sunitinib in Non-Small Cell Lung Cancer, sponsored by Genentech, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Sunitinib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 6 that started in 2007, is one of 12 in phase 2, and was the 6th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 19 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 15 under way, 8 of them phase 3. Of 162 finished, 96 (59%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 99th largest by enrollment of the 142 interventional ones that give a count, is one of 8 that started in 2007, is one of 56 in phase 2, and was the 11th registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced, recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with pleural effusions, Stage IV, or recurrent).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab · Drug: sunitinib · Drug: carboplatin · Drug: paclitaxel
Drug: bevacizumab · Drug: carboplatin · Drug: paclitaxel
Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
25 mg/day for 2 weeks, followed by 1 week of rest
On the first day of each cycle for 4 cycles
On the first day of each cycle for 4 cycles
Best Response
The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.
Time frame: From randomization until disease progression/recurrence
Serious Adverse Events
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Time frame: 60 days following the last administration of study treatment
Incidence of Grade ≥ 3 Adverse Events
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Time frame: 60 days following the last administration of study treatment
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Time frame: 60 days following the last administration of study treatment
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Time frame: 60 days following the last administration of study treatment
| Milestone | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel |
|---|---|---|
| Started | 30 | 26 |
| Completed | 0 | 0 |
| Not completed | 30 | 26 |
The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.
| participants | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 12 | 9 |
| Stable Disease | 10 | 9 |
| Progressive Disease | 2 | 1 |
| Unable to Evaluate | 0 | 0 |
| Missing | 1 | 0 |
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
| participants | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel |
|---|---|---|
| Anaemia | 0 | 1 |
| Febrile Neutropenia | 4 | 1 |
| Neutropenia | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
| Cardiac Arrest | 1 | 1 |
| Diarrhoea | 1 | 0 |
| Asthenia | 0 | 1 |
| Disease Progression | 1 | 1 |
| Fatigue | 1 | 0 |
| Pain | 0 | 1 |
| Hepatic Pain | 0 | 1 |
| Drug Hypersensitivity | 0 | 1 |
| Cellulitis | 1 | 0 |
| Bacterial Sepsis | 0 | 1 |
| Collapse of Lung | 1 | 0 |
| Platelet Count Decreased | 1 | 0 |
| Haemoglobin Decreased | 0 | 1 |
| Nutrophil Count Decreased | 0 | 1 |
| Dehydration | 2 | 1 |
| Back Pain | 1 | 0 |
| Lung Cancer Metastatic | 0 | 2 |
| Gastric Cancer | 1 | 0 |
| Non-Small Cell Lung Cancer | 1 | 0 |
| Confusional State | 0 | 1 |
| Renal Failure | 0 | 1 |
| Pleural Effusion | 0 | 2 |
| Pneumothorax | 1 | 0 |
| Chronic Obstructive Pulmonary Disease | 0 | 2 |
| Pulmonary Embolism | 2 | 0 |
| Dyspnoea | 0 | 1 |
| Haemoptysis | 0 | 1 |
| Pneumonitis | 1 | 0 |
| Pulmonary Haemorrhage | 0 | 1 |
| Nasal Septum Perforation | 1 | 0 |
| Aortic Aneurysm | 1 | 0 |
| Hypotension | 0 | 1 |
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
| participants | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel |
|---|---|---|
| Anaemia | 1 | 0 |
| Febrile Nutropenia | 4 | 2 |
| Leukopenia | 6 | 3 |
| Neutropenia | 18 | 12 |
| Thrombocytopenia | 7 | 5 |
| Cardiac Arrest | 1 | 1 |
| Left Ventricular Dysfunction | 1 | 0 |
| Diarrhoea | 1 | 1 |
| Gastrointestinal Haemorrhage | 1 | 0 |
| Asthenia | 0 | 1 |
| Disease Progression | 1 | 1 |
| Fatigue | 2 | 3 |
| Pain | 1 | 2 |
| Hepatic Pain | 0 | 1 |
| Drug Hypersensitivity | 0 | 1 |
| Hypersensitivity | 0 | 1 |
| Bacterial Sepsis | 0 | 1 |
| Cellulitis | 1 | 0 |
| Infection | 1 | 0 |
| Pneumonia | 0 | 2 |
| Collapse of Lung | 1 | 0 |
| Aspartate Aminotransferase Increased | 1 | 0 |
| Blood Alkaline Phosphatase Increased | 1 | 0 |
| Fibrin D Dimer Increased | 1 | 0 |
| Haemoglobin Decreased | 0 | 1 |
| International Normalised Ratio Increased | 1 | 1 |
| Nutrophil Count Decreased | 1 | 1 |
| Platelet Count Decreased | 4 | 0 |
| White Blood Cell Count Decreased | 2 | 0 |
| Anorexia | 1 | 0 |
| Dehydration | 2 | 1 |
| Hyperglycaemia | 0 | 2 |
| Hypoalbuminaemia | 1 | 0 |
| Hypocalcaemia | 0 | 1 |
| Hyponatraemia | 0 | 2 |
| Arthralgia | 0 | 1 |
| Back Pain | 1 | 0 |
| Muscular Weakness | 1 | 0 |
| Musculoskeletal Pain | 1 | 0 |
| Gastric Cancer | 1 | 0 |
| Lung Cancer Metastatic | 0 | 2 |
| Metastases to Central Nervous System | 1 | 0 |
| Non-Small Cell Lung Cancer | 1 | 0 |
| Dizziness | 1 | 0 |
| Confusional State | 0 | 1 |
| Albuminuria | 1 | 0 |
| Renal Failure | 0 | 1 |
| Chronic Obstructive Pulmonary Disease | 0 | 1 |
| Dyspnoea | 2 | 2 |
| Pleural Effusion | 0 | 2 |
| Pneumonitis | 1 | 0 |
| Pulmonary Embolism | 2 | 1 |
| Pulmonary Haemorrhage | 0 | 1 |
| Leukocytoclastic Vasculitis | 1 | 0 |
| Rash | 2 | 0 |
| Aortic Aneurysm | 1 | 0 |
| Hypertension | 3 | 1 |
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
| participants | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib |
|---|---|
| Anaemia | 1 |
| Febrile Nutropenia | 2 |
| Leukopenia | 4 |
| Neutropenia | 11 |
| Thrombocytopenia | 6 |
| Left Ventricular Dysfunction | 1 |
| Diarrhoea | 1 |
| Gastrointestinal Haemorrhage | 1 |
| Nausea | 1 |
| Stomatitis | 1 |
| Disease Progression | 1 |
| Fatigue | 2 |
| Bronchitis | 1 |
| Cellulitis | 1 |
| Infection | 1 |
| Collapse of Lung | 1 |
| Aspartate Aminotransferase Increased | 1 |
| Fibrin D Dimer Increased | 1 |
| International Normalised Ratio Increased | 1 |
| Neutrophil Count Decreased | 1 |
| Platelet Count Decreased | 5 |
| White Blood Cell Count Decreased | 1 |
| Anorexia | 1 |
| Dehydration | 2 |
| Hypoalbuminaemia | 1 |
| Back Pain | 1 |
| Muscular Weakness | 1 |
| Musculoskeletal Pain | 1 |
| Gastric Cancer | 1 |
| Metastases to Central Nervous System | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Dizziness | 1 |
| Albuminuria | 1 |
| Pnemothorax | 1 |
| Dyspnoea | 2 |
| Pulmonary Embolism | 2 |
| Leukocytoclastic Vasculitis | 1 |
| Rash | 1 |
| Aortic Aneurysm | 1 |
| Hypertension | 3 |
All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
| participants | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel |
|---|---|---|
| Anaemia | 1 | 0 |
| Febrile Nutropenia | 1 | 1 |
| Leukopenia | 1 | 1 |
| Neutropenia | 3 | 1 |
| Thrombocytopenia | 3 | 2 |
| Cardiac Arrest | 0 | 1 |
| Diarrhoea | 1 | 0 |
| Gastrointestinal Haemorrhage | 1 | 0 |
| Disease Progression | 1 | 2 |
| Fatigue | 2 | 1 |
| Drug Hypersensitivity | 0 | 1 |
| Hypersensitivity | 0 | 1 |
| Bronchitis | 1 | 0 |
| Infection | 1 | 0 |
| Collapse of Lung | 1 | 0 |
| Aspartate Aminotransferase Increased | 1 | 0 |
| International Normalised Ratio Increased | 1 | 0 |
| Neutrophil Count Decreased | 0 | 1 |
| Platelet Count Decreased | 5 | 0 |
| Dehydration | 2 | 0 |
| Back Pain | 1 | 0 |
| Gastric Cancer | 1 | 0 |
| Lung Cancer Metastatic | 0 | 1 |
| Metastases to Central Nervous System | 1 | 0 |
| Metastases to Liver | 0 | 1 |
| Non-Small Cell Lung Cancer | 1 | 0 |
| Albuminuria | 1 | 0 |
| Renal Failure | 0 | 1 |
| Haemoptysis | 0 | 1 |
| Pleural Effusion | 0 | 1 |
| Pneumothorax | 1 | 0 |
| Pulmonary Embolism | 2 | 0 |
| Rash | 1 | 0 |
| Aortic Aneurysm | 1 | 0 |
| Hypertension | 2 | 2 |
| Hypotension | 0 | 1 |
Collected over 60 days following the last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Carboplatin/Paclitaxel | 7/26 (26.9%) | 15/26 (57.7%) | 25/26 (96.2%) |
| Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | 11/29 (37.9%) | 17/29 (58.6%) | 28/29 (96.6%) |
| Event | Bevacizumab + Carboplatin/Paclitaxel | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/26 | 4/29 |
| Lung Cancer MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/26 | 0/29 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/26 | 0/29 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 2/26 | 0/29 |
| DehydrationMetabolism and nutrition disorders | 1/26 | 2/29 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/26 | 2/29 |
| Cardiac ArrestCardiac disorders | 1/26 | 1/29 |
| AstheniaGeneral disorders | 1/26 | 0/29 |
| Disease ProgressionGeneral disorders | 1/26 | 1/29 |
| Hepatic PainHepatobiliary disorders | 1/26 | 0/29 |
| Event | Bevacizumab + Carboplatin/Paclitaxel | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 12/26 | 18/29 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/26 | 7/29 |
| LeukopeniaBlood and lymphatic system disorders | 3/26 | 6/29 |
| Platelet count decreasedInvestigations | 0/26 | 5/29 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/26 | 4/29 |
| FatigueGeneral disorders | 3/26 | 2/29 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/26 | 0/29 |
| HypertensionVascular disorders | 3/26 | 3/29 |
| PainGeneral disorders | 2/26 | 1/29 |
| PneumoniaInfections and infestations | 2/26 | 0/29 |
| Age, Continuous(years) | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Mean | 63.7 ± 9.5 | 64.8 ± 10.7 | 64.2 ± 10.0 |
| Age, Customized(Participants) | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| <18 Years | 0 | 0 | 0 |
| Between 18 and 64 Years | 15 | 13 | 28 |
| >=65 Years | 15 | 13 | 28 |
| Sex: Female, Male(Participants) | Bevacizumab + Carboplatin/Paclitaxel + Sunitinib | Bevacizumab + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 16 | 14 | 30 |
No study locations are listed for this record.
Ran from Mar 2007 to primary completion in Apr 2008, 13 months.
Results were first posted in Aug 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sunitinib
Carcinoma, Non-Small-Cell Lung →